Tags

Type your tag names separated by a space and hit enter

The effect of atorvastatin on serum lipoproteins in acromegaly.
Clin Endocrinol (Oxf). 2005 Jun; 62(6):650-5.CE

Abstract

OBJECTIVE

Acromegaly is associated with long-term adverse effects on cardiovascular mortality and morbidity. Reducing growth hormone secretion improves well-being and symptoms, but may not significantly improve the lipoprotein profile. An additional approach to cardiovascular risk reduction in acromegaly may therefore be to target lipoprotein metabolism directly. In this study we investigated the effect of statin treatment.

DESIGN

Double blind, placebo-controlled, crossover study of the effects on circulating lipoproteins of atorvastatin 10 mg daily vs. placebo. Each treatment was given for 3 months in random order.

SUBJECTS

Eleven patients with acromegaly.

MEASUREMENTS

Lipids, lipoproteins, apolipoproteins, enzyme activity and calculated cardiovascular risk.

RESULTS

Atorvastatin treatment compared to placebo resulted in a significant decrease in serum cholesterol (5.85 +/- 1.04 mmol/l vs. 4.22 +/- 0.69 mmol/l; mean +/- SD; P < 0.001), low-density lipoprotein (LDL) cholesterol (2.95 +/- 1.07 mmol/l vs. 1.82 +/- 0.92 mmol/l; P < 0.001), very low-density lipoprotein (VLDL) cholesterol (0.31 (0.21-0.47) mmol vs. 0.23 (0.13-0.30) mmol/l median (interquartile range); P < 0.05), apolipoprotein B (111 +/- 28 mg/dl vs. 80 +/- 18 mg/dl; P < 0.001), and calculated coronary heart disease risk (6.8 (3.3-17.9) vs. 2.8 (1.5-5.7)% over next 10 years; P < 0.01). Serum triglyceride was 1.34 (1.06-1.71) mmol/l on placebo and 1.14 (0.88-1.48) mmol/l on atorvastatin (ns). HDL cholesterol, apolipoprotein A1 and Lp(a) concentrations and cholesteryl ester transfer protein and lecithin: cholesterol acyl transferase activities were also not significantly altered.

CONCLUSION

Atorvastatin treatment was safe, well tolerated and effective in improving the atherogenic lipoprotein profile in acromegaly.

Authors+Show Affiliations

Cardiovascular, Medicine and Surgery Central Clinical Academic Group, University of Manchester, M13 9PT, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15943824

Citation

Mishra, Manoj, et al. "The Effect of Atorvastatin On Serum Lipoproteins in Acromegaly." Clinical Endocrinology, vol. 62, no. 6, 2005, pp. 650-5.
Mishra M, Durrington P, Mackness M, et al. The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf). 2005;62(6):650-5.
Mishra, M., Durrington, P., Mackness, M., Siddals, K. W., Kaushal, K., Davies, R., Gibson, M., & Ray, D. W. (2005). The effect of atorvastatin on serum lipoproteins in acromegaly. Clinical Endocrinology, 62(6), 650-5.
Mishra M, et al. The Effect of Atorvastatin On Serum Lipoproteins in Acromegaly. Clin Endocrinol (Oxf). 2005;62(6):650-5. PubMed PMID: 15943824.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of atorvastatin on serum lipoproteins in acromegaly. AU - Mishra,Manoj, AU - Durrington,Paul, AU - Mackness,Mike, AU - Siddals,Kirk W, AU - Kaushal,Kalpana, AU - Davies,Rob, AU - Gibson,Martin, AU - Ray,David W, PY - 2005/6/10/pubmed PY - 2005/8/12/medline PY - 2005/6/10/entrez SP - 650 EP - 5 JF - Clinical endocrinology JO - Clin Endocrinol (Oxf) VL - 62 IS - 6 N2 - OBJECTIVE: Acromegaly is associated with long-term adverse effects on cardiovascular mortality and morbidity. Reducing growth hormone secretion improves well-being and symptoms, but may not significantly improve the lipoprotein profile. An additional approach to cardiovascular risk reduction in acromegaly may therefore be to target lipoprotein metabolism directly. In this study we investigated the effect of statin treatment. DESIGN: Double blind, placebo-controlled, crossover study of the effects on circulating lipoproteins of atorvastatin 10 mg daily vs. placebo. Each treatment was given for 3 months in random order. SUBJECTS: Eleven patients with acromegaly. MEASUREMENTS: Lipids, lipoproteins, apolipoproteins, enzyme activity and calculated cardiovascular risk. RESULTS: Atorvastatin treatment compared to placebo resulted in a significant decrease in serum cholesterol (5.85 +/- 1.04 mmol/l vs. 4.22 +/- 0.69 mmol/l; mean +/- SD; P < 0.001), low-density lipoprotein (LDL) cholesterol (2.95 +/- 1.07 mmol/l vs. 1.82 +/- 0.92 mmol/l; P < 0.001), very low-density lipoprotein (VLDL) cholesterol (0.31 (0.21-0.47) mmol vs. 0.23 (0.13-0.30) mmol/l median (interquartile range); P < 0.05), apolipoprotein B (111 +/- 28 mg/dl vs. 80 +/- 18 mg/dl; P < 0.001), and calculated coronary heart disease risk (6.8 (3.3-17.9) vs. 2.8 (1.5-5.7)% over next 10 years; P < 0.01). Serum triglyceride was 1.34 (1.06-1.71) mmol/l on placebo and 1.14 (0.88-1.48) mmol/l on atorvastatin (ns). HDL cholesterol, apolipoprotein A1 and Lp(a) concentrations and cholesteryl ester transfer protein and lecithin: cholesterol acyl transferase activities were also not significantly altered. CONCLUSION: Atorvastatin treatment was safe, well tolerated and effective in improving the atherogenic lipoprotein profile in acromegaly. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/15943824/The_effect_of_atorvastatin_on_serum_lipoproteins_in_acromegaly_ L2 - https://doi.org/10.1111/j.1365-2265.2005.02273.x DB - PRIME DP - Unbound Medicine ER -